Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24411297 | 1.00 | EPHX1 (0.36) | EPHX1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL820473 | 1.00 | EPHX1 (0.36) | EPHX1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL375503 | 1.00 | EPHX1 (0.36) | EPHX1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL29819835 | 1.00 | EPHX1 (0.36) | EPHX1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL2954122 | 1.00 | EPHX1 (0.36) | EPHX1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL2962701 | 0.93 | ALDH1A1 (0.39) | EPHX1ALDH1A1HSD17B10SMN1; SMN2KLK7 | |
| SCHEMBL13199587 | 0.93 | ALDH1A1 (0.39) | EPHX1ALDH1A1HSD17B10SMN1; SMN2KLK7 | |
| SCHEMBL22980251 | 0.90 | CHRM2 (0.35) | EPHX1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL2023504 | 0.87 | HSD17B10 (0.40) | EPHX1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL6095020 | 0.87 | HSD17B10 (0.40) | EPHX1CHRM2CHRM1CHRM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| WO-2022261154-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-1729763-A4 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1729763-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | Bristol-Myers Squibb Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005089118-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | EPHX1 2891/4885CHRM2 3723/4885CHRM1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.